Date:1/24/2011

lant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.

Amgen Inc.Condensed Consolidated Statements of Income andReconciliation of GAAP Earnings to "Adjusted" Earnings(In millions, except per share data)(Unaudited)Three Months EndedThree Months EndedDecember 31, 2010December 31, 2009GAAPAdjustments

"Adjusted"GAAPAdjustments

"Adjusted"Revenues:Product sales$ 3,760$   -$
3,760$ 3,743$
-$
3,743Other revenues81-8166-66Total revenues3,841-3,8413,809-3,809Operating expenses:Cost of sales (excludes amortization of certain acquired intangible assets presented below)572(4)

(a)568538(3)

(a)535Research and development854(11)

(a)825891(9)

(a)864(18)

(b)(18)

(b)Selling, general and administrative1,156(14)

(a)1,1421,180(15)

(a)1,159(6)

(f)Amortization of certain acquired intangible assets73(73)

(c)-73(73)

(c)-Other 118(118)

(d)-4(5)

(e)-1

(f)Total operating expenses2,773(238)2,5352,686(128)2,558Operating income1,0682381,3061,1231281,251Interest expense, net162(68)

(g)94142(64)

(g)78Interest and other income, net93-9394-94Income before income taxes9993061,3051,0751921,267(Benefit) provision for income taxes(23)107

(h)20214458

(h)202113

(i)5

(j)Net income $ 1,022$  81$
,103$
931$ 134$
,065Earnings per share:Basic $   1.09$
.17$   0.93$
.06Diluted (l)$   1.08$'/>"/>

SOURCE Amgen Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. PLC Systems Reports Fourth Quarter 2007 Results
5. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
8. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
9. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
10. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
11. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments